NCT01605318 (Clinical Trial/ Labetuzumab-SN-38 / IMMU-130 / hMN-14-SN38)

Study Title
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer (NCT01605318)

Trial Description
This is a Phase I/II, open-label study of IMMU-130 (also known as Labetuzumab-SN-38 or hMN-14-SN38) administered in 21-day treatment cycles, once or twice weekly for 2 consecutive weeks followed by one week of rest for patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen. The study is being done to evaluate whether the study drug is safe and tolerable at different dose levels with these dosing schedules and to obtain preliminary information on its efficacy.

This trial is sponsored by Immunomedics. [1]

Study Data

  • Condition:
  • Interventions:
    • Drugs used in this trial
      • IMMU-130 (Labetuzumab-SN-38; hMN-14-SN38)
  • Phase: I & II
  • Estimated Enrollment: 104
  • Start: September 2012
  • Estimated Completion: December 2015
  • Last verified: January 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: September 28, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.